Asthma and chronic obstructive pulmonary disease (COPD) cause significant morbidity and mortality worldwide. In the context of disease pathogenesis, both asthma and COPD involve chronic inflammation of the lung and are characterised by the abnormal release of inflammatory cytokines, dysregulated immune cell activity and remodelling of the airways. To date, current treatments still only manage symptoms and do not reverse the primary disease processes. In recent work, interleukin (IL)-1α and IL-1β have been suggested to play important roles in both asthma and COPD. In this review, we summarise overwhelming pre-clinical evidence for dysregulated signalling of IL-1α and IL-1β contributing to disease pathogenesis and discuss the paradox of IL-1 therapeutic studies in asthma and COPD. This is particularly important given recent completed and ongoing clinical trials with IL-1 biologics that have had varying degrees of failure and success as therapeutics for disease modification in asthma and COPD. Interleukin-1 signalling plays a major contributory role in the pathogenesis of asthma and COPD http://bit.ly/2qHSvEM

中文翻译：

---

白细胞介素 1 信号在哮喘和 COPD 发病机制中的作用的当前观点

哮喘和慢性阻塞性肺疾病 (COPD) 在世界范围内导致显着的发病率和死亡率。在疾病发病机制的背景下，哮喘和 COPD 都涉及肺部的慢性炎症，其特征是炎性细胞因子的异常释放、免疫细胞活性失调和气道重塑。迄今为止，目前的治疗仍然只能控制症状，不能逆转原发疾病过程。最近的研究表明，白细胞介素 (IL)-1α 和 IL-1β 在哮喘和 COPD 中发挥重要作用。在这篇综述中，我们总结了 IL-1α 和 IL-1β 信号失调导致疾病发病机制的压倒性临床前证据，并讨论了哮喘和 COPD 中 IL-1 治疗研究的悖论。鉴于最近已完成和正在进行的 IL-1 生物制剂临床试验作为哮喘和 COPD 疾病改善疗法的失败和成功，这一点尤为重要。Interleukin-1 信号传导在哮喘和 COPD 的发病机制中起主要作用 http://bit.ly/2qHSvEM